Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FT218 in Idiopathic Hypersomnia
NCT06525077Phase 3Completed
- Sponsor
- Avadel Pharmaceuticals
- Start
- Aug 2024
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of AV001 in idiopathic hypersomnia (IH), sponsored by Avadel Pharmaceuticals. Started Aug 2024; status: completed.
02
Drugs
AV001
03
Conditions
idiopathic hypersomnia (IH)
Beyond the preview
Go deeper on NCT06525077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06525077.